Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company’s $6 billion forecast – CNBC

Moderna's announcement, which came ahead of its presentation at the annual JPMorgan Healthcare Conference, shows the steep drop in demand for Covid products last year as cases and public concern about the virus dwindled from their pandemic peaks. Weakening demand for the company's shot, its only commercially available product, led shares of Moderna to fall nearly 45% last year.

Roughly $6.1 billion of Moderna's revenue related to the shot came from sales of the vaccine. Another $600 million was deferred revenue related to the company's work with Gavi, a nongovernmental global vaccine organization that coordinated a global shot distribution program, Moderna said in a release.

Moderna, during its third-quarter earnings report in November, forecast at least $6 billion in full-year Covid vaccine sales, but did not provide a range for that guidance. Notably, that forecast did not include contributions from Gavi, Moderna CFO Jamey Mock told CNBC during an interview.

In August, before the rollout of its latest version of the jab, the company said it expected the shot to rake in between $6 billion and $8 billion in revenue.

The company noted that the vaccine won 48% of the U.S. Covid vaccine market share last year. That's up from the 37% market it captured in 2022.

The size of the U.S. market for Covid shots in 2023 is likely around 40 million and 60 million doses during the fall and winter season, which is consistent with what the nation saw in 2022, according to Mock.

But the biotech company expects sales from the shot to drop even further in 2024. It reiterated its companywide full-year sales guidance of roughly $4 billion on Monday. Notably, that forecast includes revenue from its vaccine against respiratory syncytial virus, or RSV, which could win U.S. Food and Drug Administration approval in April.

Moderna said it expects to return to sales growth in 2025 with the launch of new products. The company currently has 45 products in development, nine of which are in late-stage trials. They include Moderna's combination shot targeting Covid and the flu, which could win approval as early as 2025.

Mock said combination vaccines should be "very helpful" in terms of providing more convenience to patients and health-care providers and reducing the costs of goods sold, among other factors, which might have a positive impact on Covid vaccination rates overall.

The company said it expects to "break even" by 2026.

Don't miss these stories from CNBC PRO:

The rest is here:

Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast - CNBC